Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
Patent Number: US9255927
Executive Summary:
General Description:
The goal of all targeted therapies and personalized medicine in general is to define which patients are most or least likely to benefit or have toxicity from a given treatment and to provide patients with a more accurate prognosis. Multiple groups have shown that increased levels of various angiogenesis factors, including VEGF, correlate with worse prognosis or outcome in general. However, in the clinic, markers that predict which patients will derive greater or lesser benefit from anti-VEGF therapy have been elusive. This is the first method attempted to solve the issue.
Scientists at Duke University have come up with a method involving detection of the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. They also have come up with a method involving detection of the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer to develop a prognosis for a subject with pancreatic cancer.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Andrew B. Nixon
https://medicine.duke.edu/faculty/andrew-benjamin-nixon-phd
Executive Summary:
- Invention Type: Prognostic
- Patent Status: Issued (Grant date: 2016-02-09)
- Patent Link: https://patents.google.com/patent/US9255927/
- Research Institute: Duke University
- Disease Focus: Pancreatic cancer
- Basis of Invention: Multiple groups have shown that increased levels of various angiogenesis factors, including VEGF, correlate with worse prognosis or outcome in general
- How it works: Detects the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Detecting the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer to develop a prognosis for a subject with pancreatic cancer
- Lead Challenge Inventor: Andrew B. Nixon
- Inventors: Nixon; Andrew B. (Durham, NC), Hurwitz; Herbert I. (Durham, NC), Pang; Herbert (Durham, NC), Starr; Mark D. (Durham, NC)
- Development Stage: Tested in 328 patients
- Novelty: The first time a group has attempted to develop methods for predicting responsiveness of a pancreatic cancer to anti-VEGF therapies, as well as a method of developing a prognosis for a subject diagnosed with pancreatic cancer
- Clinical Applications: Determining the course of therapy in patients with pancreatic cancer
General Description:
The goal of all targeted therapies and personalized medicine in general is to define which patients are most or least likely to benefit or have toxicity from a given treatment and to provide patients with a more accurate prognosis. Multiple groups have shown that increased levels of various angiogenesis factors, including VEGF, correlate with worse prognosis or outcome in general. However, in the clinic, markers that predict which patients will derive greater or lesser benefit from anti-VEGF therapy have been elusive. This is the first method attempted to solve the issue.
Scientists at Duke University have come up with a method involving detection of the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. They also have come up with a method involving detection of the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer to develop a prognosis for a subject with pancreatic cancer.
Strengths:
- First set of biomarkers proposed to determine the effectiveness of an anti-VEGF therapy in patients with pancreatic cancer
- First set of biomarkers proposed to determine a prognosis for a subject with pancreatic cancer receiving anti-VEGF therapy
Weaknesses:
- Has to be tested in larger clinical trials
Patent Status:
- Priority date: 2011-05-05
- Filing date: 2012-05-07
- Publication date: 2016-02-09
- Grant date: 2016-02-09
Inventor Bio: Andrew B. Nixon
https://medicine.duke.edu/faculty/andrew-benjamin-nixon-phd
